Nuwellis, DaVita partner on ultrafiltration therapy pilot program

Nuwellis (Nasdaq:NUWE) announced today that it entered into a supply and collaboration agreement with DaVita (NYSE:DVA).

The agreement enables Nuwellis — formerly CHF Solutions — to pilot its Aquadex ultrafiltration therapy within selected U.S. markets. Aquadex, which removes excess fluid from patients suffering from hypervolemia (fluid overload), treats congestive heart failure and related conditions.

DaVita offers extracorporeal therapies like continuous renal replacement therapy and apheresis. The company recently launched a joint dialysis venture with Medtronic called “Mozarc Medical.”

Pairing Aquadex with DaVita’s care team could expand access to ultrafiltration therapy, Nuwellis said. The company also aims for this deal to reduce related healthcare costs for providers and payers.

“We are honored that DaVita is collaborating with Nuwellis to pilot a services model alongside Aquadex,” said Nestor Jaramillo, Jr., president and…

Read more
  • 0

Medtronic and DaVita’s dialysis venture appears to be called Mozarc Medical
Regulatory filings indicate a medtech CEO is involved in the new kidney care company.

Medtronic has filed trademark applications for this Mozarc logo. [Image via the U.S. Patent and Trademark Office]Clues are pointing to Mozarc Medical as the name of the new kidney care company that Medtronic (NYSE:MDT) and DaVita (NYSE:DVA) are expected to launch this year.

The companies used “NewCo” as a placeholder when announcing the new company last year and said a renaming and rebranding would come when the deal closes sometime in 2023.

Since then, Medtronic has filed trademark applications with the U.S. Patent and Trademark Office for Mozarc and Mozarc Medical relating to dialysis products.

Medtronic listed itself as the applicant on five applications filed in August and December. Four more recent applications, filed in January, list Mozarc Medical US LLC as the applicant. All list the same attorney of record and the address of Medtronic’s Fridley, Minnesota headquarters.

Meanwhile, law firm DLA Piper — which represents Medtro…

Read more
  • 0

Medtronic, DaVita to form new kidney care company

Medtronic (NYSE:MDT) and DaVita (NYSE:DVA) today announced the intent to form a new medical device company for kidney care.

The new, independent company — dubbed “NewCo” — aims to enhance the patient treatment experience and improve overall outcomes for kidney care patients.

According to a news release, the new company will bring together Medtronic’s capabilities as a healthcare technology leader and DaVita’s expertise as a comprehensive kidney care provider. NewCo will focus on developing a wide range of novel kidney care products and solutions, including future home-based products to make different dialysis treatments more accessible.

“This is an exciting moment that will shape the future of kidney care,” Ven Manda, president of Medtronic’s renal care solutions business and NewCo’s CEO upon close, said in the release. “Our singular focus on end-to-end kidney health solutions will position this new c…

Read more
  • 0

Fresenius to provide more home dialysis machines to DaVita

A NxStage home hemodialysis machine [Image courtesy of Fresenius Medical Care] Fresenius Medical Care North America (FMCNA) has expanded its agreement with DaVita Kidney Care to provide NxStage home hemodialysis machines and related technology to DaVita’s U.S. patients.

“We are excited to expand our longstanding collaboration with DaVita to help more patients benefit from the portability, dependability, and flexibility of our NxStage home machines, which are designed to be easy to use,” Joe Turk, president of Home and Critical Care Therapies for FMCNA, said in a news release out today.

Under the agreement, DaVita patients will also access Nx2me Connected Health, a connected health platform that simplifies collection and sharing of treatment information with the dialysis clinic and care team. Nx2me Connected Health accesses treatment information directly from home hemodialysis machines.

Keith Hartman, group vice president for DaVita home modalities, sa…

Read more
  • 0

CMS delays shift to new payment model for chronic kidney disease treatments

CMS will now wait until Jan. 1, 2022 to start its Kidney Care Choices model, meant to shift the way the U.S. treats chronic kidney disease.

The new payment model was supposed to start on Jan. 1 of this year, but health providers are still grappling with the COVID-19 pandemic.

The new model could have a major effect on dialysis treatment providers including DaVita Healthcare (NYSE:DVA) and Fresenius Medical Care (NYSE:FMS; ETR:FRE). Baxter (NYSE:BAX) meanwhile announced in 2019 that it was investing in technologies to support the effort.

The new model’s roots go back to former President Donald Trump’s 2019 executive order to emphasize transplants and home hemodialysis over in-clinic treatment. End-stage renal disease is one of the few conditions in the United States where there is already a single-payer system, thanks to a law signed by President Richard Nixon in 1972.

The Kidney Care Choices (KCC) model would provide strong financial i…

Read more
  • 0